These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

882 related items for PubMed ID: 8349820

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R, Ellerbeck E, Garrison L, Midthun K, Clements ML, Clayman B, Fernie B, Smith G.
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [Abstract] [Full Text] [Related]

  • 6. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
    Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath MJ, Matthews TJ, Wright PF, Belshe RB, Clements ML, Dolin R.
    J Infect Dis; 1994 Oct; 170(4):782-6. PubMed ID: 7930718
    [Abstract] [Full Text] [Related]

  • 7. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA.
    J Immunol; 1993 Jun 15; 150(12):5647-65. PubMed ID: 8515081
    [Abstract] [Full Text] [Related]

  • 8. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML.
    AIDS Res Hum Retroviruses; 1994 Dec 15; 10(12):1713-23. PubMed ID: 7888231
    [Abstract] [Full Text] [Related]

  • 9. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
    Bolmstedt A, Sjölander S, Hansen JE, Akerblom L, Hemming A, Hu SL, Morein B, Olofsson S.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul 15; 12(3):213-20. PubMed ID: 8673525
    [Abstract] [Full Text] [Related]

  • 10. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C, McLain L, Dimmock NJ.
    AIDS Res Hum Retroviruses; 1994 Feb 15; 10(2):205-12. PubMed ID: 8198873
    [Abstract] [Full Text] [Related]

  • 11. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 15; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B, Inman J, Highet P, Blackburn R, Manischewitz J, Blyveis N, Angus RD, Golding H.
    J Virol; 1995 Jun 15; 69(6):3299-307. PubMed ID: 7745677
    [Abstract] [Full Text] [Related]

  • 14. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB.
    Vaccine; 1994 Aug 15; 12(10):912-8. PubMed ID: 7975833
    [Abstract] [Full Text] [Related]

  • 15. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX.
    AIDS Res Hum Retroviruses; 2005 Jan 15; 21(1):58-67. PubMed ID: 15665645
    [Abstract] [Full Text] [Related]

  • 16. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB.
    AIDS Res Hum Retroviruses; 1999 Jan 20; 15(2):115-32. PubMed ID: 10029244
    [Abstract] [Full Text] [Related]

  • 17. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW, Vujcic LK, Glass WL, Seamon KB, Rastogi SC, Hendry RM, Boulos R, Nzila N, Quinnan GV.
    AIDS Res Hum Retroviruses; 1991 Oct 20; 7(10):831-8. PubMed ID: 1720630
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, Milman G.
    AIDS; 1994 Feb 20; 8(2):169-81. PubMed ID: 7519019
    [Abstract] [Full Text] [Related]

  • 19. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?
    Clements GJ, Price-Jones MJ, Stephens PE, Sutton C, Schulz TF, Clapham PR, McKeating JA, McClure MO, Thomson S, Marsh M.
    AIDS Res Hum Retroviruses; 1991 Jan 20; 7(1):3-16. PubMed ID: 2015114
    [Abstract] [Full Text] [Related]

  • 20. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD.
    Proc Natl Acad Sci U S A; 1993 Mar 15; 90(6):2443-7. PubMed ID: 8460155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.